期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 12, 期 7, 页码 883-903出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.12.7.883
关键词
autoimmune disease; BTK; Bruton's tyrosine kinase; common gamma; chain; cytokines; delayed-type hypersensitivity; dry eye; DTH; inflammation; IRAK-4; JAK-3; Janus kinase; p38; PKC theta; psoriasis; rheumatoid arthritis; rho kinase; SCID; severe combined immunodeficiency; STAT; signal transducers and activators of transcription; TYK; Tyrosine kinase gamma c; XID; X-linked immunodeficiency; XLA; X-linked agammaglobulinemia
At the time of writing, there are seven marketed kinase inhibitor drugs. The first kinase inhibitor, imatinib mesilate (Gleevec (R), Novartis), came to market in 2001, an inhibitor of the breakpoint cluster region (BCR)/Abelson murine leukemia oncogene homolog (ABL) fusion, platelet-derived growth factor (PDGF) receptor, and c-kit kinases. The most recent kinase inhibitor to come to market, disatinib (Sprycel (R), Bristol-Myers Squibb), acts on c-SRC, ABL and Bruton's tyrosine kinase. To date, kinase inhibitor drugs are approved for oncology and demonstrate that it is possible to develop compounds with relative selectivity for the target kinase against the broader kinome. However, the use of kinase inhibitors in chronic inflammatory and immunologic diseases may require greater selectivity for the target kinase. This review addresses the opportunities and challenges of kinase inhibition as a therapeutic approach in chronic immune and inflammatory disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据